NPCE (NeuroPace) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


NPCE NeuroPace Inc NPCE
65 GF Score
Price $16.64
GF Value $11.41
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is NeuroPace Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

NeuroPace's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

NPCE vs TCMD, BVS, CTKB: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Devices subindustry, NeuroPace's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroPace Margin of Safety % (DCF Earnings Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroPace's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where NeuroPace's Margin of Safety % (DCF Earnings Based) falls into.


NPCE
65GF Score
NeuroPace Inc NPCE
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is NeuroPace (NPCE) Overvalued in 2026?

Based on GuruFocus' analysis, NeuroPace stock appears to be overvalued. The current stock price of $16.64 is trading 45.8% above its estimated GF Value™ of $11.41. GuruFocus considers NeuroPace to be Significantly Overvalued.

Key valuation signals for NPCE:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $11.41 vs. price of $16.64 (45.8% above fair value)
  • GF Score™: 65/100 with 4 warning signs

No single metric tells the full story. See the NPCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeuroPace Business Description

Address 455 N. Bernardo Avenue, Mountain View, CA, USA, 94043
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
65GF Score

Get the complete analysis for NPCE

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.64
Price
$11.41
GF Value